Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A combination clinical study of G1T48/lerociclib regimen for ER+, HER2- breast cancer

Trial Profile

A combination clinical study of G1T48/lerociclib regimen for ER+, HER2- breast cancer

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs G1T-48 (Primary) ; Lerociclib (Primary)
  • Indications Breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors G1 Therapeutics
  • Most Recent Events

    • 29 Sep 2019 According to a G1 Therapeutics media release, based on safety and tolerability findings in the Phase 1b portion of this trial, the company selected the 600 mg and 1,000 mg doses of G1T48 for evaluation in the ongoing Phase 2a portion and will use these data to select the dose for the pivotal trial.
    • 07 Aug 2019 According to a media release, the company is planning to initiate this study in 2020.
    • 24 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top